2020
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial
Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology 2020, 40: 1331-1341. PMID: 32926247, DOI: 10.1007/s10067-020-05342-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntirheumatic AgentsDouble-Blind MethodHumansQuality of LifeSeverity of Illness IndexSpondylitis, AnkylosingTreatment OutcomeConceptsHealth-related qualityDisease activityWeek 52Work Limitations QuestionnaireIntravenous golimumabWeeks 0Week 16Functioning outcomesEQ-5D-5L indexPlacebo-crossover groupProductivity loss scoresEffective treatment optionVisual analog scaleConclusionsIn patientsPlacebo groupSpondylitis QualityAdult patientsAnalog scaleEQ-VASWeek 28Treatment optionsProductivity outcomesWeek 8GolimumabHRQoL
2017
Treat to Target in Axial Spondyloarthritis: What Are the Issues?
Danve A, Deodhar A. Treat to Target in Axial Spondyloarthritis: What Are the Issues? Current Rheumatology Reports 2017, 19: 22. PMID: 28386759, DOI: 10.1007/s11926-017-0648-6.Peer-Reviewed Original ResearchMeSH KeywordsAntirheumatic AgentsBiological ProductsDrug MonitoringEarly DiagnosisHumansSeverity of Illness IndexSpondylarthritisTreatment OutcomeConceptsT2T strategyAxial spondyloarthritisT2TPsoriatic Arthritis TrialRandomized clinical studyChronic medical conditionsLimited therapeutic optionsRoutine clinical practiceT strategyLack of evidenceAggressive managementPsoriatic arthritisRadiographic outcomesRheumatic diseasesRheumatoid arthritisClinical evidenceTherapeutic optionsArthritis trialsClinical trialsClinical studiesMedical conditionsClinical practiceTarget strategyArthritisSpondyloarthritis
2014
Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis
Danve A, Reddy A, Vakil-Gilani K, Garg N, Dinno A, Deodhar A. Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis. Clinical Rheumatology 2014, 34: 117-124. PMID: 25421013, DOI: 10.1007/s10067-014-2827-4.Peer-Reviewed Original Research